...of blockbusters.Check out some of the recent press, the...

...of blockbusters.

Check out some of the recent press, the successes to date have been quite spectacular. And VHL owns an entire platform dedicated to Therapeutic Vaccines which has been proven in phase II trials (Transgene), and phase Ib trials by VHL.... not long now till phase II results. If transgene can boast a billion market cap, I wonder what Virax can do if they get some excellent phase II results. Any guesses?

"Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness"

http://www.live-pr.com/en/stakeholder-opinions-therapeutic-vaccines-r1048421230.htm

http://www.fiercevaccines.com/story/new-brain-cancer-vaccines-target-tumor-cells/2010-03-11

"projected sales in 2014 of $1.07bn, Provenge is valued at $4.87bn according to EvaluatePharma's NPV Analyzer, just above the Seattle companys market capitalisation. Dendreon has no products on the market and behind Provenge only two products in phase I trials, the anti-HER2 cancer vaccine Neuvenge and D-3263, a Trp-p8 agonist it is co-developing with Roche (RHHBY.PK) for cancer and benign prostatic hyperplasia."

http://seekingalpha.com/article/192340-investors-show-confidence-in-dendreon